Evidence map›Paper›PMID 33252191›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2020

Direct Antimicrobial Susceptibility Testing on Clinical Urine Samples by Optical Tracking of Single Cell Division Events.

Fenni Zhang, Jiapei Jiang, Michelle McBride, Yunze Yang, Manni Mo, Rafael Iriya, Joseph Peterman, Wenwen Jing, Thomas Grys, Shelley E Haydel and 2 more

Open access · greenAbstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Fenni ZhangBiodesign Center for Bioelectronics and Biosensors, Arizona State University, Tempe, AZ, 85287, USA.ORCID 0000-0002-4369-8563
Jiapei JiangBiodesign Center for Bioelectronics and Biosensors, Arizona State University, Tempe, AZ, 85287, USA.
Michelle McBrideBiodesign Center for Bioelectronics and Biosensors, Arizona State University, Tempe, AZ, 85287, USA.
Yunze YangBiodesign Center for Bioelectronics and Biosensors, Arizona State University, Tempe, AZ, 85287, USA.
Manni MoBiodesign Center for Bioelectronics and Biosensors, Arizona State University, Tempe, AZ, 85287, USA.
Rafael IriyaBiodesign Center for Bioelectronics and Biosensors, Arizona State University, Tempe, AZ, 85287, USA.
Joseph PetermanBiodesign Center for Bioelectronics and Biosensors, Arizona State University, Tempe, AZ, 85287, USA.
Wenwen JingBiodesign Center for Bioelectronics and Biosensors, Arizona State University, Tempe, AZ, 85287, USA.ORCID 0000-0003-1038-5509
Thomas GrysDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Shelley E HaydelBiodesign Center for Bioelectronics and Biosensors, Arizona State University, Tempe, AZ, 85287, USA.
Nongjian TaoBiodesign Center for Bioelectronics and Biosensors, Arizona State University, Tempe, AZ, 85287, USA.
Shaopeng WangBiodesign Center for Bioelectronics and Biosensors, Arizona State University, Tempe, AZ, 85287, USA.
BioElectronics (United States) · USMayo Clinic Hospital · USTempe Union High School District · US

Funding

Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cellsR01AI138993 · NIAID · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI WANG, SHAOPENG · 2018 to 2022
$5.5M
NIAID NIH HHS R01 AI138993
6 · The paper itself

Abstract

With the increasing prevalence of antibiotic resistance, the need to develop antimicrobial susceptibility testing (AST) technologies is urgent. The current challenge has been to perform the antibiotic susceptibility testing in short time, directly with clinical samples, and with antibiotics over a broad dynamic range of clinically relevant concentrations. Here, a technology for point-of-care diagnosis of antimicrobial-resistant bacteria in urinary tract infections, by imaging the clinical urine samples directly with an innovative large volume solution scattering imaging (LVSi) system and analyzing the image sequences with a single-cell division tracking method is developed. The high sensitivity of single-cell division tracking associated with large volume imaging enables rapid antibiotic susceptibility testing directly on the clinical urine samples. The results demonstrate direct detection of bacterial infections in 60 clinical urine samples with a 60 min LVSi video, and digital AST of 30 positive clinical samples with 100% categorical agreement with both the clinical culture results and the on-site agar plating validation results. This technology provides opportunities for precise antibiotic prescription and proper treatment of the patient within a single clinic visit.

Indexed as

Urinary Tract InfectionsAnti-Bacterial AgentsBacteriaCell DivisionHumansMicrobial Sensitivity TestsAnti-Bacterial Agentsantibiotic resistanceantimicrobial susceptibility testingEscherichia coliintrinsic featuresoptical imagingsingle-cell division trackingurinary tract infections

Identifiers

PMID33252191
PMCPMC7770081
OpenAlexW3108911692

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.